Logo
x

Search

Subscribe Now

Greater China

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and B...

  • November 10, 2021
Zai Lab Entered into an Exclusive License Agreement with Karuna Therapeutics to Develop and Commercialize KarXT (xanomeline-trospium) in Greater China

Zai Lab Entered into an Exclusive License Agreement with Karuna Therapeutics to Develop and Commercialize KarXT (xanomeline-trospi...

  • November 10, 2021
Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

  • October 22, 2021
Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

  • October 12, 2021
BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop & Commercialize Plinabulin in Greater China

BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop & Commercialize Plinabulin in Greater China

  • August 27, 2021
Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China

Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China

  • August 17, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.